Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploratory Clinical Study of Camrelizumab Combined With Pirfenidone and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

NCT07161791 is registered in ClinicalTrials.gov with Harbin Medical University as lead sponsor.

NCT NCT07161791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07161791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploratory Clinical Study of Camrelizumab Combined With Pirfenidone and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer
Lead sponsor
Harbin Medical University
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
September 15, 2025
Completion date
December 31, 2027
Enrollment
12 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, triple negative breast cancer (tnbc)